Multiple Sclerosis Therapeutic Market By Drug Class (Immunomodulators, Immunosuppressants, Interferons, Monoclonal Antibodies, Corticosteroids, Others), By Disease Type (Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Progressive-Relapsing Multiple Sclerosis (PRMS)), By Route of Administration (Oral, Injectable {Intravenous (IV), Subcutaneous (SC), Intramuscular (IM)}), By End-User (Hospitals, Specialty Clinics, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons
• Monoclonal Antibodies
• Corticosteroids
• Others

By Disease Type

• Relapsing-Remitting Multiple Sclerosis (RRMS)
• Secondary Progressive Multiple Sclerosis (SPMS)
• Primary Progressive Multiple Sclerosis (PPMS)
• Progressive-Relapsing Multiple Sclerosis (PRMS)

By Route of Administration

• Oral
• Injectable
  • Intravenous (IV)
  • Subcutaneous (SC)
  • Intramuscular (IM)

By End-User

• Hospitals
• Specialty Clinics
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Biogen
• Novartis
• Roche
• Merck & Co.
• Sanofi
• Bayer
• Genzyme
• Teva Pharmaceuticals
• AbbVie
• Celgene
• Johnson & Johnson
• Eisai
• Mylan
• Sandoz
• Almirall
• Horizon Therapeutics
• UCB Pharma
• Amgen